# Selank

**Category:** peptide
**Evidence Grade:** C
**Risk Profile:** low

## Description
A synthetic analogue of the immunomodulatory peptide tuftsin, developed at the Institute of Molecular Genetics (Russia). Approved as an anxiolytic in Russia. Enhances BDNF expression and has nootropic and immune-modulating properties.

## Mechanisms of Action
- BDNF upregulation
- GABA modulation
- Immune system modulation (IL-6, T-helper balance)
- Enkephalin stabilization

## Dosage
- **Standard:** 250-500mcg intranasal, 1-3x/day
- **Range:** 150-750mcg/day
- **Notes:** Intranasal administration. Approved in Russia. Typical course is 2-4 weeks.

## Key Findings
- Approved anxiolytic in Russia with clinical trial data
- Increased BDNF mRNA expression in hippocampus (animal studies)
- Anxiolytic without sedation or cognitive impairment

## Interactions
- Theoretical interaction with benzodiazepines or other GABAergic drugs

## Side Effects
- Nasal irritation
- Mild fatigue (rare)

## Contraindications
- Pregnancy
- Autoimmune conditions (theoretical)

## Sources


## Suppliers


---
*Last updated: 2026-02-04T14:50:14.774Z*
